The novel synthetic serine protease inhibitor CU-2010 dose-dependently reduces postoperative blood loss and improves postischemic recovery after cardiac surgery in a canine model

被引:13
作者
Szabo, Gabor [1 ]
Veres, Gabor [2 ]
Radovits, Tamas [1 ]
Haider, Humaira [1 ]
Krieger, Nelli [1 ]
Baehrle, Susanne [3 ]
Niklisch, Silke [4 ]
Miesel-Groeschel, Christiane [1 ]
van de Locht, Andreas [4 ]
Karck, Matthias [1 ]
机构
[1] Heidelberg Univ, Dept Cardiac Surg, D-69120 Heidelberg, Germany
[2] Semmelweis Univ, Sch Med, Dept Cardiovasc Surg, Budapest, Hungary
[3] Heidelberg Univ, Dept Cardiol Angiol & Pulmonol, D-69120 Heidelberg, Germany
[4] Medicine Co, Munich, Germany
关键词
BYPASS GRAFT-SURGERY; THROMBIN GENERATION; PLATELET-FUNCTION; APROTININ; TRANSFUSION; REPERFUSION; METAANALYSIS; DYSFUNCTION; REDUCTION; ISCHEMIA;
D O I
10.1016/j.jtcvs.2009.10.059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Serine protease inhibitors such as aprotinin reduce perioperative blood loss and may improve post-pump cardiac performance owing to their anti-inflammatory properties. After the "aprotinin era,'' we investigated the efficacy of the novel synthetic serine protease inhibitors CU-2010 with improved coagulatory and anti-inflammatory profile on blood loss and reperfusion injury in a canine model. Methods: Thirty-six dogs were divided into 6 groups: control, aprotinin (n = 8; Hammersmith scheme), and CU-2010 (0.5, 0.83, 1.25, and 1.66 mg/kg). All animals underwent 90 minutes of cardiopulmonary bypass with 60 minutes of hypothermic cardioplegic arrest. End points were blood loss during the first 2 hours after application of protamine, as well as recovery of myocardial contractility (slope of the end-systolic pressure-volume relationship, coronary blood flow, and vascular reactivity. Results: CU-2010 dose-dependently reduced blood loss to a degree comparable with that of aprotinin at lower doses and even further improved at higher doses (control/aprotinin/CU-2010 in increasing doses: 142 +/- 13, 66 +/- 17, 95 +/- 16, 57 +/- 17, 46 +/- 3, and 13 +/- 4 mL; P < .05). Whereas aprotinin did not influence myocardial function, CU-2010 improved the recovery of end-systolic pressure-volume relationship (control 60 +/- 6 mg kg vs aprotinin 73 +/- 7 mg/kg vs CU-2010 1.66 mg/kg; 102% +/- 8%; P < .05). Coronary blood flow (52 +/- 4 vs 88 +/- 7 vs 96 +/- 7; P < .05) and response to acetylcholine (44% +/- 6% vs 77% +/- 7% vs 81% +/- 6%; P < .05) were improved by both aprotinin and CU-2010. Conclusions: The novel serine protease inhibitor CU-2010 significantly reduced blood loss after cardiac surgery comparable with aprotinin. Furthermore, an additionally improved anti-inflammatory profile led to a significantly improved postischemic recovery of myocardial and endothelial function. (J Thorac Cardiovasc Surg 2010; 139: 732-40)
引用
收藏
页码:732 / 740
页数:9
相关论文
共 35 条
[1]   Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery [J].
Avidan, MS ;
Alcock, EL ;
Da Fonseca, J ;
Ponte, J ;
Desai, JB ;
Despotis, GJ ;
Hunt, BJ .
BRITISH JOURNAL OF ANAESTHESIA, 2004, 92 (02) :178-186
[2]   The impact of aprotinin on blood loss and blood transfusion in off-pump coronary artery bypass grafting [J].
Bittner, Hartmuth B. ;
Lemke, Janine ;
Lange, Michelle ;
Rastan, Ardawan ;
Mohr, Friedrich W. .
ANNALS OF THORACIC SURGERY, 2008, 85 (05) :1662-1668
[3]  
BLAUHUT B, 1991, J THORAC CARDIOV SUR, V101, P958
[4]  
BOISCLAIR MD, 1993, BLOOD, V82, P3350
[5]   Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery [J].
Brown, Jeremiah R. ;
Birkmeyer, Nancy J. O. ;
O'Connor, Gerald T. .
CIRCULATION, 2007, 115 (22) :2801-2813
[6]   Effects of aprotinin on gene expression and protein synthesis after ischemia and Reperfusion in rats [J].
Buerke, Michael ;
Pruefer, Diethard ;
Sankat, Dennis ;
Carter, Justin M. ;
Buerke, Ute ;
Russ, Martin ;
Schlitt, Axel ;
Friedrich, Ivar ;
Boergermann, Jochen ;
Vahl, Christian F. ;
Werdan, Karl .
CIRCULATION, 2007, 116 (11) :I121-I126
[7]   Low molecular weight protamine: A potent but nontoxic antagonist to heparin/low molecular weight protamine [J].
Byun, Y ;
Chang, LC ;
Lee, LM ;
Han, IS ;
Singh, VK ;
Yang, VC .
ASAIO JOURNAL, 2000, 46 (04) :435-439
[8]   The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery [J].
Cammerer, U ;
Dietrich, W ;
Rampf, T ;
Braun, SL ;
Richter, JA .
ANESTHESIA AND ANALGESIA, 2003, 96 (01) :51-57
[9]   Anti-inflammatory actions of aprotinin provide dose-dependent cardioprotection from reperfusion injury [J].
Carter, J. M. ;
Buerke, U. ;
Roessner, E. ;
Russ, M. ;
Schubert, S. ;
Schmidt, H. ;
Ebelt, H. ;
Pruefer, D. ;
Schlitt, A. ;
Werdan, K. ;
Buerke, M. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 155 (01) :93-102
[10]   Effects of aprotinin dosage on renal function? [J].
Dietrich, Wulf ;
Busley, Raimund ;
Boulesteix, Anne-Laure .
ANESTHESIOLOGY, 2008, 108 (02) :189-198